Vaccines to Reduce Antimicrobial Resistance to Bacterial Pathogens

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Pathogens-host Immune Interface".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 3458

Special Issue Editors


E-Mail Website
Guest Editor
CIBER of Infectious Diseases, Biomedical Research Institute A Coruña, University Hospital A Coruña, A Coruña, Spain
Interests: nosocomial pathogens; bacterial vaccines; antimicrobial resistance; host-pathogen interactions; immune response
Special Issues, Collections and Topics in MDPI journals

E-Mail
Co-Guest Editor
Intrahospital Infections Department, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
Interests: vaccines against high priority pathogens; antimicrobial resistance and virulence; K. pneumoniae pathogenesis; epidemiology

E-Mail
Co-Guest Editor
Laboratorio de Infecciones Intrahospitalarias, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
Interests: Klebsiella pneumoniae; vaccines; intestinal colonization; high risk clones

Special Issue Information

Dear Colleagues,

The rise of antimicrobial resistance has led to the inefficacy of drugs and persistent infections, which consequently increase the risk of severe illness and the spread of disease. To combat antimicrobial resistance, an integrated approach that includes vaccines and antibiotics is needed. Vaccines play a crucial role in preventing infections caused by resistant bacteria, thereby reducing the reliance on antibiotics and slowing the spread of resistance.

This Special Issue aims to provide an overview of advancements in the development of bacterial vaccines targeting antimicrobial-resistant pathogens. The scope of this Special Issue includes the following topics: (i) novel technologies and approaches to the production of bacteria vaccines, (ii) vaccination-induced immune responses, (iii) mucosal vaccines and vaccination, and (iv) the use of vaccines as tools for combating antimicrobial resistance. We welcome the submission of research papers, short communications, and reviews related to these topics.

Dr. Miriam Moscoso
Dr. Astrid Pérez
Dr. Eva Gato
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial resistance
  • immune responses
  • infectious diseases
  • bacterial vaccines
  • antibody response
  • cellular response
  • mucosal immunity
  • efficacy evaluation
  • vaccine development

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 2311 KiB  
Review
Klebsiella pneumoniae Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease
by Jernelle C. Miller, Alan S. Cross, Sharon M. Tennant and Scott M. Baliban
Vaccines 2024, 12(10), 1177; https://doi.org/10.3390/vaccines12101177 - 17 Oct 2024
Cited by 4 | Viewed by 2938
Abstract
Klebsiella pneumoniae is well recognized as a serious cause of infection in healthcare-associated settings and immunocompromised individuals; however, accumulating evidence from resource-limited nations documents an alarming rise in community-acquired K. pneumoniae infections, manifesting as bacteremia and pneumonia as well as neonatal sepsis. [...] Read more.
Klebsiella pneumoniae is well recognized as a serious cause of infection in healthcare-associated settings and immunocompromised individuals; however, accumulating evidence from resource-limited nations documents an alarming rise in community-acquired K. pneumoniae infections, manifesting as bacteremia and pneumonia as well as neonatal sepsis. The emergence of hypervirulent and antibiotic-resistant K. pneumoniae strains threatens treatment options for clinicians. Effective vaccination strategies could represent a viable alternative that would both preempt the need for antibiotics to treat K. pneumoniae infections and reduce the burden of K. pneumoniae disease globally. There are currently no approved K. pneumoniae vaccines. We review the evidence for K. pneumoniae lipopolysaccharide (LPS) as a vaccine and immunotherapeutic target and discuss the role of antibodies specific for the core or O-antigen determinants within LPS in protection against Klebsiella spp. disease. We expand on the known role of the Klebsiella spp. capsule and O-antigen modifications in antibody surface accessibility to LPS as well as the in vitro and in vivo effector functions reported for LPS-specific antibodies. We summarize key hypotheses stemming from these studies, review the role of humoral immunity against K. pneumoniae O-antigen for protection, and identify areas requiring further research. Full article
(This article belongs to the Special Issue Vaccines to Reduce Antimicrobial Resistance to Bacterial Pathogens)
Show Figures

Figure 1

Back to TopTop